Getting Drugs Across Biological Barriers

Yang, Rong; Wei, Tuo; Goldberg, Hannah; Wang, Weiping; Cullion, Kathleen; Kohane, Daniel S.

doi:10.1002/adma.201606596

Cited by 172 publications

(151 citation statements)

References 298 publications

(392 reference statements)

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, nanomaterial formulations for the treatment of topical conditions (e.g., psoriasis) have been more heavily investigated . The review of Yang et al addresses drug delivery across the skin barrier in a complete and detailed manner …”

Section: Therapeutic Nanomaterials—possible Routes Of Exposurementioning

confidence: 99%

Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials

et al. 2018

View full text Add to dashboard Cite

Realization of the immense potential of nanomaterials for biomedical applications will require a thorough understanding of how they interact with cells, tissues, and organs. There is evidence that, depending on their physicochemical properties and subsequent interactions, nanomaterials are indeed taken up by cells. However, the subsequent release and/or intracellular degradation of the materials, transfer to other cells, and/or translocation across tissue barriers are still poorly understood. The involvement of these cellular clearance mechanisms strongly influences the long-term fate of used nanomaterials, especially if one also considers repeated exposure. Several nanomaterials, such as liposomes and iron oxide, gold, or silica nanoparticles, are already approved by the American Food and Drug Administration for clinical trials; however, there is still a huge gap of knowledge concerning their fate in the body. Herein, clinically relevant nanomaterials, their possible modes of exposure, as well as the biological barriers they must overcome to be effective are reviewed. Furthermore, the biodistribution and kinetics of nanomaterials and their modes of clearance are discussed, knowledge of the long-term fates of a selection of nanomaterials is summarized, and the critical points that must be considered for future research are addressed.

show abstract

Section: Therapeutic Nanomaterials—possible Routes Of Exposurementioning

confidence: 99%

Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials

et al. 2018

View full text Add to dashboard Cite

show abstract

“…barrier to virtually all molecules (16), despite its thinness (human TMs are 10-μm to 100-μm thick) (17). The low permeability of the TM is mostly due to its outermost layer, the stratum corneum, which blocks all but the smallest lipophilic molecules (18). We have used chemical permeation enhancers (CPEs) to reversibly enhance transtympanic delivery of ciprofloxacin, a broad-spectrum fluoroquinolone currently used for OM when tympanostomy tubes are in place (19).…”

Section: Introductionmentioning

confidence: 99%

Treatment of Streptococcus pneumoniae otitis media in a chinchilla model by transtympanic delivery of antibiotics

Yang¹,

Sabharwal²,

Shlykova³

et al. 2018

JCI Insight

Self Cite

View full text Add to dashboard Cite

“…CL5‐MeHA MN patches also penetrate across viable epidermis (50–120 μm) and reach the superficial dermis. This allows the released drug to diffuse and reach the capillary blood supply in the dermal layer for circulation in the body …”

Section: Resultsmentioning

confidence: 99%

A self‐adhesive microneedle patch with drug loading capability through swelling effect

Chew

Shah

Zheng

et al. 2020

Bioengineering & Transla Med

View full text Add to dashboard Cite

Microneedles (MNs) offer a rapid method of transdermal drug delivery through penetration of the stratum corneum. However, commercial translation has been limited by fabrication techniques unique to each drug. Herein, a broadly applicable platform is explored by drug-loading via swelling effect of a hydrogel MN patch. A range of small molecule hydrophilic, hydrophobic, and biomacromolecule therapeutics demonstrate successful loading and burst release from hydrogel MNs fabricated from methacrylated hyaluronic acid (MeHA). The post-fabrication drug loading process allows MeHA MN patches with drug loadings of 10 μg cm −2 . Additional post-fabrication processes are explored with dendrimer bioadhesives that increase work of adhesion, ensuring stable fixation on skin, and allow for additional drug loading strategies.

show abstract

Getting Drugs Across Biological Barriers

Cited by 172 publications

References 298 publications

Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials

Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials

Treatment of Streptococcus pneumoniae otitis media in a chinchilla model by transtympanic delivery of antibiotics

A self‐adhesive microneedle patch with drug loading capability through swelling effect

Contact Info

Product

Resources

About